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L  INTRODUCJ]ON 
Every year, large amounts of  new synthetic drugs are produced in Member States of 
the  European Union.  The  consumption  of these drugs· is  on  the  rise,  particularly 
among very young people.  This development poses a serious threat to their health 
and lives and it is a source of  great distress to our citizens. They expect urgent action 
at all levels to reverse this trend. 
Firm  action  in  this  area  is  also  needed  to  maintaining  the  credibility  of the 
considerable efforts the European Union is. undertaking in combatting the cultivation 
and production of  narcotic drugs throughout the world. 
The sharp increase of illicit  production,  trafficking and  use of these new synthetic 
drugs in Europe can be attributed to several factors which make them different from 
more traditional plant-based drugs. These include: 
•  the ingredients needed for their production are all available within the EU, meaning that 
they can ~  produced locally, close to the areas of  consumption. 
•  they are relatively easy to prepare, with precursors freely  available in the market and 
requiring only a rather unsophisticated infrastructure such as abandoned warehouses or 
even mobile homes; 
•  they are cheaper than cocaine or other plant based drugs which are the other "more 
traditional, main stimulants in illicit markets and have a longer-lasting effect; 
•  they are seen as fashionable and part of  youth culture in some countries.  There is no 
strong link with theft or violent crime; 
•  the public health risk is frequently underestimated in public perception.  It is not always 
easy  to  recognize  the  difference  with  similar,  licit  products  which  are  often  used 
functionnally, e.g. in certains professions to increase endurance. 
They  do,  however,  also  have  features  in  common with  plant-based  drugs,  notably  the 
analogous threat they can pose to human health and the danger they represent, partiOJlarly 
to young people. 
1 The  Community  action  programme  on  the  prevention  of drug  dependence  already 
contributes to improving  public  awareness and  developing appropriate  health  and  social 
responses  to  this  threat.  In  particular,  this  programme  currently  gives  support  to 
transnational ·pilot  projects  aiming  to  build  up  a  system  to  recognise  trends  in  drugs 
consumption among the young, to assess pr~ence  of  drug use in particular settings such 
as Techno-scenes and to develop transnational exchange of  data. 
The  European Commission,  acting  together with  the  Presidency  of the  Council  of 
Ministers and the European Parliament, has on several occasions highlited this problem 
and  called  for  priority action at  the level  of the European Union.  The fight  against 
drugs became a central theme during  the Irish Presidency and  the Dublin European 
Council clearly pointed out the need to supress domestic production and trafficking of 
synthetic drugs within our Member States. 
This  Communication represents the Commission's contribution to following  up  that 
instruction. 
ll.  NATURE OF THE PROBLEM 
The world-wide nature of  the problem is reflected in the. increasing attention directed to it 
in the relevant international organisations within the United Nations family: World Health 
Organisation, International Narcotics Control Board, Conunission on Narcotic Drugs. 
There exists a major international legal instrument for taclding the problem at world leveL 
in the shape of  the 1971 United Nations Convention on Psychotropic Substances. 
Ratified  and  implemented  by  146  nations,  and  subsequently  enhanced  by  the  relevant 
provisions of  the 1988 United Nations Convention against Dlicit Traffic in Narcotic Drugs 
and  Psychotropic  .Substances,  the  1971  Convention  offers  the  essential  international 
framework for the scheduling and interdiction of  the main synthetic drugs identified at that 
time  as  posing  a  danger  to  health.  It  contains  an  updating  mechanism,  but  recent 
experience has shown that this mechanism, requiring a world-wide international consensus, 
is  slow to mobilise - and  certainly not flexible  or rapid  enough to keep  pace with  the 
appearance on the market of  new synthetic drugs often deliberately designed to circumvent 
the Convention's provisions. 
The European Union and its Member States are,  however,  equipped -especially since the 
entry into force of  the TEU - with a range of  instruments and possibilities to react quickly 
and  effectively  among  themselves  to  address  the  moving  target  represented  by  new 
~~cdrugs.  . 
2 Synthetic drugs, like plant-based drugs, are dependent upon certain precursor chemicals. Of 
the 22 substances controlled through EC legislation in implementation of  the 1988 United 
Nations  Convention,  8 are  directly  relevant to synthetic drugs 
1 and  others  need  to  be 
added. 
Furthermore, with regard to end products (i.e.  thO synthetic drugs  thernsel~ as opposed 
to their precursor chemicals) aU EU Member States have introduced in their legislation the 
control of  the psychotropic substances placed  unci~ control by the 1971  UN Convention 
(see ANNEX D. This Convention provides for the control of classified substances on the 
basis of  their strict chemical definition. 
Since,  however,  the amphetamine-type  Stimulants are ve:ry  similar· in  chemi~ structure, 
they lend themselves easily to minor  structUral  modifications to  lead to  a different  end-
product.  These modifications can be motivated by various factors : 
(i)  the deliberate effort to circl}mvent legislation on precursors or. 
(ii)  the possible use and availability of  non-listed precwsors; 
(iii)  the deliberate manufacturing of  amphetamine-eype stimulants not covered by 
national law or international convention, and sOmetimes referred to as "designer 
drugs". 
It is chemically possible to obtain a large number of  structures altered in this way, in which 
however  the  basic  composition  of the  amphetamine  remains  .unchanged.  Some  such 
derivatives  currently  popular  in  Europe  thus  fill  outside  the  scope  of the  1971  UN 
Convention on Psychotropic Substances.  Althoush in theory this problem could be tackled 
though regular modification of  any of  the lists· ofthe I  971  UN Convention, such a process 
can be expected to take 2-3 years. Thus an important lacuna can exist between the moment 
when new synthetic drugs are introduced in ~  illicit market and when they are added to 
one of the lists of the UN Convention.  During this ·intervening period,  and  unless other 
defences are mounted, there is a risk· that the new synthetic drup can circulate freely since 
the criminal law of  several Member States does not allow  control to be legally excerased 
on substances which are not (yet) put under a Hst of  controlled substances.  ·  , 
m.  SOME RqPONSES AT NATIONAL LEVEL 
In countries  affected  by  the  problem  of synthetic  drugs,  three  di1ferent  categories  of 
response appear to have ~  adopted, in addition to the control system based on the strict 
chemical  definition of the substances (the comrol "by name"  of  the substance) which  is 
foreseen in the 1971 UN Convention on Psychotropic Substances : 
1  phenyl-2-propanone  (P2P),  ephedrine, p~  safrole,  isosaftole,  piperonal, 
·3,4 methylenedioxy-P2P and phenylacetic acid. 
3 (i)  the "generic IPj)Oach" : 
some Member States (United' Kingdom.  Ireland)  have introduced  in  their  misuse  of 
drugs legislation the use of generic definitions for various families  of drugs to catch 
those  new  synthetic  drugs  which  do  not  appear  on  the  Schedules  of the  UN 
Conventions.  In Germany,  a new bill which would introduce the generic approach is 
being discussed at the intenninisteriallevel and with the Under before being presented 
at Parliament. 
The use of  generic definitions has the advantage of  criminalising by anticipation a great 
number of groups  of  synthetic  drugs  that  could  eventually  appear  on  the  market. 
Although it can not cover all  the potential  drugs of abuse which  may  eventually be 
produced  on the basis of a single  molecular structure,  it  makes  it  more difficult  for 
clandestine laboratories to produce synthetic drugs which remain outside of  the scope 
of  criminal law; 
(ii)  the "emergency Jist" am?roach 
other  Member  States  (Germany,  The  Netherlands)  have  introduced  into  their 
legislation  an  urgency  procedure  to  control .  legally,  on  a  provisional  basis,  new 
substances which appear on the market before the full introduction of  these new drugs 
into the relevant schedule.  This system allows for a quick reaction to the abuse of  and 
trafficking in "new" synthetic drugs and can give rise to the use of  criminal sanctions; 
(iii) the "analogue" approach : 
this is the system preferred by the US Drugs Enforcement Agency and is set out in the 
1986  amendment  to  the  Controlled  Substances  Act  (CSA)  in  the  form  of the 
Controlled Substance Analogue Enforcement Act. 
This Act provides that criminal sanctions apply to the activity of manufacturing  and 
distributing "controlled substance analogues" intended for human consumption. These 
substances  are  considered  "analogues"  if they  produce  substantially  the  same 
psychoactive effect as controlled substances and have chemical structures substantially 
similar to  those  of controlled  substances.  These  substances are  therefore  prohibited 
unJess  it  is concluded  in  a court of law that  the  assumptions  were  unfounded.  Tt  is 
important to note that  there is  no  list  of controlled  substance  analogues.  Since  the 
introduction  of the  1986  amendment,  the  DEA  have  observed  a decrease  in  the 
production  and  distribution  of analogues  and  attribute  this,  in  particular,  to  the 
analogue statute which has had the effect of making the trafficking of new synthetic 
drugs too risky and uncertain to be worth the effort for the profit involved. 
4 IV.  ELEMENTS FOR A RESPONSE AT THE LEVEL OF THE EUROPEAN UNION 
THE DUBLIN EUROPEAN COUNCll... 
Heads of  State and Government, meeting in Dublin in December 1996, identified the issue 
of synthetic  drugs  as  needing  priority  attention  both  within  the  European  Union  and 
between  the  Union  and  third  countries,  particularly  the  Central  and  Eastern  European 
countries.  In doing so,  they specifically endorsed the report on drugs  they had received 
from the Council. and the Joint Action of  17 December 1996 concerning the approximation 
of  the laws and practices ofthe Member States in the field of  drugs. 
The report in question stated clearly that synthetic drugs was an area "where insufficiencies 
exist" and "needed to be tackled  ~t three levels:· (a)  l~slation; (b) practical cooperation 
against  production  and  trafficking,  including  improved  cooperation  between  national 
authorities and the chemical industry; and (c) international cooperation". 
As for the Joint Action, it states in its Article 5 that there is.a need for more convergence in 
Member States legislation  in  the area of synthetic drugs  and  provides that the Member 
States "shall endeavour to draft convergentlegil1ation to the ex/en/necessary to make up 
legal ground or fill legal vacuums as regards synt~tic dntgs.  In particrtlar they shall . 
promote the  el1ablishment of  a  rapid irifomiation system  to enable .  sztch ·  dntgs to  be 
identified as sztbstances liable to be prohibited a.s .roan aft  they appear anywhere in a 
Member State". 
Thus the European Council has given clear guidance on how it wishes to see the problem 
addressed. The Commission considers that this invitation to ensure an appropriate and swift 
control on new synthetic drugs and their chemical  precursors should be followed  up  by 
means of  a number of  initiatives, which could be taken on a step by step basis. 
As a first and early step, the Commission favours action on three fronts: 
- chemica]  precursoiJ  (starting  material):  Proposals  for  amending  the  existing 
Directive and Regulation will be presented by the Commission by October 1997. 
- new synthetic drugs (end-products): the creation of an early warning system for 
synthetic drugs, including a mechanism for risk. assessment . 
- a commitment by Member States to criminalise production and trafficking of  new 
synthetic drugs declared dangerous. 
There is also a case for an examination at EU level of  whether at a later stage additional 
instruments might enhance the effectiveness of  the fight against the illicit trafficking in and 
use  of synthetic  drugs,  based  perhaps  on  a  discussion  of the  relative  merits  of the 
"emergency list" approach,  the "generic approach'' or the " analogue approach" mentioned 
.~nder chapter m  above. 
s ACTIQN FORESEEN ON PRECURSOR OF NEW SYNJHETIC DRUGS 
An  effective  way  of approaching  the· problem  of new  synthetic  drugs  consists  in 
ensuring a better monitoring of  the trade in the chemical substances whic~ are the basic 
ingredients used in manufacturing new synthetic drugs. 
It is not possible to monitor this trade under the classical methods of control such as 
those provided for under the present Community legislation on precursors. The nature 
of the  chemicals  involved  and  the  particular conditions  under which  new  synthetic 
drugs can be manufactured impede the use of  these strict control mechanisms. 
This is the reason why a broad consensus exists at the international level to look for 
other monitoring mechanisms such as a "special surveillance list", that would be more 
flexible for both trade and  public authorities and thus would be really efficient,  given 
this  specific  context.  This  is  in  particular the  approach  the US.DEA  follows,  more 
stringent mechanisms ·being unrealistic in this case. 
Technical work is currently in progress in the competent Community fora.  They  will 
result  in  formal  proposals by  the  Commission,  to  be  presented  to  the Council ·next 
October, after further discussions-with the Member states and the relevant trade and 
chemical industries organisations. 
These proposals will address the following aspects: 
. - list of  new products to be monitored, 
- new methods for the monitoring of  the products concerned, 
- ways and means of  adapting rapidly in the future the list of  these products. 
They will  concern amendment  of the  existing  directive  concerning  manufacture  and 
placing  on  the  market  of the  chemical  substances  concerned  within  the  EU  and 
amendment of  the regulation concerning the international trade. 
Mor~over, when  a common  position  has  been· adopted  within  the  Council  on  this 
question,  the  Commission  intends  to· ask  for  a  negotiation  mandate  vis-a-vis  the 
Central and Eastern European Countries on the territory of  which new synthetic drugs 
are produced.  In parallel, the Phare programme resources will be used to continue to 
help  these  countries  to  prepare  and  to  adapt  their  own  legislation  on  precursors, 
namely in view of  their accession to the EU. 
Finally, some efforts will  have to be made in short term,  in order to allow the EU to 
speak with one voice within the international meetings that should take place from next 
July,  in  view of the  preparation of the  1998  UN  General  Assembly  Special  Session 
which wilf be devoted to drugs and in which precursors will occupy a  large place. 
6 The  Commission  will  do  the  necessary  work  in  order to  ensure  that  the  necessary 
· coordination is done within the Council  and  that it  results  in  a concrete Community 
position on this topic, thus allowing the EU to maintain a leading and constructive role 
in these international fora. 
Details of  this action are described in Annex II. The input of  Member States experts in 
this process will be very important for achieving the objectives for action described in 
this Annex. 
CREATION OF  AN EARLY WARNING SYSTEM 
An effective early warning system for new synthetic drugs appearing in the Member States 
should build on existing information gathering bodies and avoid duplication. In addition to , 
national sources, the two most appropriate such bodie$ at EU level are the Europol Drugs 
unit (EDU) for information coming from the Jaw enforcement ~es,  and the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA), by means of  the national 
focal points ofREITOX, for information coming from the health and social services.  . 
To  this  can  be  added  data  concerning  chemical  precursors  diverted  into  the  illicit 
manufacture of  synthetic drugs which will continue to be examined by the Drugs Precursors  .. 
Committee set  up  under  Regulation  3677/90  and  Directive  92/109  to  which  the  early 
warning system will provide an added value. 
All this relevant information will need to be assessed by experts in order to evaluate the 
risks posed by these new substances. 
The Commission believes that this assessment would best be carried out in the framework 
of  a Technical Committee to be set up, which would involve representatives from not only 
Member States but also from the existing relevant agencies.(EMCDDA; the Agency for the 
Evaluation of  Medicinal  Products~ and the Europol Drugs Unit) . The Commission would 
seem· to be the right  institution to chair such a committee,  as  well  as contributing to its 
work on the basis of  information on synthetic drugs coming from the existing Community 
instruments  related  to  (i)  the  international  control  and  intra-Community  surveillance  of 
chemical  precursors,  (ii)  the  Community  action  programme  on  the  prevention  of drug 
dependence, (iii) the Community framework research and development programme. 
The Committee, having conducted its risk assessment on the basis of  the information from 
different  sources  (law  enforcement,  health  1&114  social  services)  should  make  its 
recommendation for action at the level  of the Council,  including,  where appropriate and 
agreed,  action  to  ban  and  criminalise  the  production  and  trafficking  of the  dangerous 
substances identified. 
7 CO-OPERATION WITH CENTRAL AND EASTERN EUROPEAN COUNTRIES 
Co-operation between EU Member· States and the Central and Eastern European countries 
in  fighting  against  illicit  drugs  trafficking,  in  particular  synthetic  drugs,  received  special 
attention at the seminar and meeting of  the Council's Drugs and Organised Crime Working 
Group with  the countries of  Central and Eastern Europe and the Baltic States which took 
place  on 23-24  October,  1996.  This  gave  rise  to  a number of useful  recommendations 
which should be followed up: 
•  Development of a network of law enforcement focal  points for synthetic drugs and  drug 
precursors between Member States Clf th European Union,  the countries of Central  and 
Eastern Europe and  the Baltic  States,  making  use  of the  existing  list  of contact  points 
maintained  in  connection  with  the  European  Community  legislation  on  the  control  of 
precursors; 
•  Combatting misuse of  synthetic drugs and precursors by: 
the building of a network of expertise from  the European  Union  and  associated 
countries to  facilitate the enhancement of the ·knowledge necessary to. tackle the 
problem,  as  well  as  the  rapid .  exchange  of information  (profiling,  production 
methods, etc.) and the adoption of  the necessary legal provisions; 
the  surveillance of non-listed  precursors used  in  illicit  production.  involving  co-
operation by law enforcement and other appropriate authorities. To this extent the 
importance of  voluntary agreement and concluding Memoranda of  Understanding 
with the trade were underlined. 
•  In the field of  precursors, adaptation of  the relevant PHARE project to ensure that the pre-
accession  procedures  presently underway  (adaptation  of legislation  to  EU  standards,  ie 
Regulation  3677/90  and  Directive  92/109)  reflect  any  possible  amendment  of the  EU 
legislation to cover chemicals diverted for the illicit manufacture of  new synthetic drugs. 
CO-OPERATION WITH OIHER KEY EU PARTNERS 
Given the global and growing nature of this  synthetic drugs  problem,  as reflected  in the 
Resolution  adopted  at  the  1995  UN  Commission  on  Narcotic  Drugs  (CND)  and  in  a 
number  of expert  meetings  which  have  taken  place  within  the  UN  bodies  concerned, 
particularly UNDCP and WHO,  it would be appropriate also to share the EU's thinking 
with its main partners, notably the USA, Canada and Japan. 
This  could  in  tum lead to possible joint  initiatives  with  them  in  international  fora,  for 
example at  the UN Commission on N&n".otic Drugs (CND) in view of  the forthcoming UN 
General Assembly (UNGA) special session on drugs (1998). 
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- ACTION AQAJNST fRECU&SQRS OF ~W  SYNlliEIIC QRUGS-
1.  The issue 
Compared  with  other types  of drugs  and  psychotropic  substances,  the  emergence  and 
development  of new  synthetic  drugs  (NSDs)  poses  a  special  problem  because  their 
chemical structure changes frequently and because many types of precursors (themselves 
very variable) can be used for making them. 
Since almost all of  these:; chemical substances are used for legal purposes, action is needed 
to prevent them  from  being diverted to  the  illicit  manufacture of synthetic  drugs.  This 
could  be  done  by  drawing  up  suitable  monitoring  measures  that  would  reconcile  the 
legitimate interests of  business with the imperatives of  action to combat synthetic drugs. 
In view of the very changeable nature of this phenomenon and the wide range of basic 
chemical sUbstances that can be used, a targeted response is required.  And as NSDs can 
be  very  simple  to  produce,  with  "recipes"  available  on  the  Internet  or  in  specialist 
publications,  there is also  the question of whether it  is  wise to  make  public the  list  of 
precursors to be monitored. 
The NSDs affecting the European  Union are mostly produced in certain Member States 
and  in a number of Central  and Eastern European countries.  The response  in  terms of 
controls on precursors therefore has to cover both the commercial use of these products 
inside the Community and trade with non-member countries. 
A unifonn response across the entire Union is essential, since supplies to traffickers would 
otherwise  quickly  be  diverted  to  Member  States  where  there  was  no  monitoring 
m~hanism. 
The threat of NSDs is not confined solely to Europe. Meetings of experts are therefore 
under  way  at  international  level.  In  particular,  mention  should ·be  made  of the  two 
meetings already held under the auspices of the United Nations from  12 to  16 February 
1996  in  Vienna  and  from  25  to  29  November  1996  in  Shanghai.  In  addition  the 
Commission,  together  with  the  US  Drug  Enforcement  Administration, · organized  an 
international conference on precursors from  11  to  14 February 1997 in Prague, at which 
the substances used to produce NSDs received considerable attention. 
The extraordinary UN General Assembly to be held in 1998 on the fight against drugs will 
boost  the  effort  to  tackle  the  problem.  Several  preparatory  meetings  are  already 
scheduled, starting in July, and  it is vital for the Community to define a common position 
on the. Issue fairly quickly in order to be able to make a positive contribution to the debate 
so that real progress can be made in the fight against new synthetic drugs. 
(i 2. ·  Current lnislation on· precunon 
Community  legislation  on  precursors  involves  a  two-pronged  approach  to  cover  the 
internal and the external aspects. 
On the internal side, the basic legislation is Council Directive 92/1 09/EEC, amended by 
Commission Directive 93/46/EEC and supplemented by Commission Regulation 1485/96. 
The scope of  the Directive covers the production and marketing of  the 22 internationally 
scheduled substances (1988 Vienna Convention). In outline, the mechanisms that apply on 
the internal front are: 
transactions  leading  to  the  marketing  of classified  substances  (both  substances 
produced in the Community and those put into free circulation are covered) must be 
documented; this includes a declaration by the' customer on their use; 
documents  must  be  kept  available  for  inspection  by  the  authorities  and  classified 
substances must be labelled; 
...,  operators  producing  or  marketing  category  I  substances  must  be  licensed  and 
authorization is required to be supplied with, possess or handle them; 
cooperation between the public authorities and operators is required. 
The  external  arrangements  are  based  on  Council  Regulation  (EEC)  No  3677/90,  as 
amended by Regulation (EEC) No 900/92. Implementing rules have been adopted by the 
Commission.  The aim  is  to regulate exports of the 22  scheduled  substances,  imposing 
obligations as regards: 
commercial documents, commercial records and the labelling of  substances; 
the licensing and registering of  operators; 
cooperation between public authorities and economic operators; and 
the issuing of  export authorizations. 
These arrangements are backed up by specific agreements concluded by the Community 
with certain  non-member countries.  At  present there are agreements with  the Andean 
countries, Mexico and the United States.  Negotiations are under way with Canada, the 
Mercosur countries, Chile and the ASEAN countries. A special clause on combating the 
diversion  of precursors  has  also  been  included  in  most  association  or  economic 
cooperation agreements concluded with non-member countries. 
3.  The weaknesses of  current legislation with manl to the problem of NSDs 
The mechanisms established by the instruments cited above are inadequate to deal with 
the problem ofNSDs. The main shortcomings are: (a) Monitoring mechanisms involved 
The current system relates to a limited number of products (22), with strict controls laid 
down  by  the  Directive  and  the  Regulation.  The  nature  of the  controls  reflects  the 
diversion  methods  likely to affect  the products  in  question,  depending  in  particular on 
their  nature,  their  availability  on  the  market  and  the  type  of drug  or  psychotropic 
substance they can be used to make. 
To control  exports,  an  export  authorization  (individual  or comprehensive)  is  required, 
. depending  on  the volume of substances traded  or the  country of destination.  In  some 
cases  authorization  is  granted  only  if an  import  authorization  is  first  issued  in  the 
destination  country.  Although  simplifications  have  been  introduced  wherever  possible, 
using  criteria  such  as  the  integrity  and  competence  of the  applicant,  the  system 
nevertheless imposes considerable constraints on the econ~mic operators concerned. 
These  constraints  cannot  be  extended  too  far,  since  any  restrictive  system  will  only 
function  well  if it  is  targeted  and  involves  no  more  than  a  reasonable  number  of 
substances and obligations.  It must also be borne in mind that besides these meehanisms, 
close and fruitful  cooperation has been established between the national authorities and 
operators  under  the  Community  legislation.  Broadening  the  constraints  rashly  would 
inevitably  undermine  such  .cooperation  and  hence  the  effectiveness  of the  entire 
arrangements to combat the diversion of  precursors. 
(b) Type and number of  substances subject to monitoring 
The  Community  legislation  currently  covers  22  substances,  only  8 of which  relate  to 
synthetic drugs (including methaqualone and LSD).  The international efforts referred to 
earlier  and  the  work  done  in  the  Community  committee  on  precursors  have  identified 
many other substances used to manufacture NSDs. 
At present there is no agreement or scientifically backed view on which precursors should 
be  subject  to  monitoring  at  Community  level.  The  main  options  range  between  6 and 
62 new substances.  There is,  however,  a general consensus (among economic operators 
and monitoring authorities) that it would be inappropriate and impossible in  practice to 
apply  to  these  substances  the  mechanisms  provided· for  by  the  current  Community 
legislation.  · 
The Union's main partners, and notably the USA, all take the same view and are working 
to draw up a "special monitoring list" involving new monitoring methods. 
4.  The problems that have to be tackled 
These issues can be grouped under four headings: 
What  products should be included to meet  current requirements?  Is there a lawful 
use for all the products concerned? Which ones can be lawfully used so widely that 
monitoring them would be impossible or undesirable? What  monitoring  mechanisms  (covering  substances  themselves  and  suspect 
transactions or orders) should be set up so that  the system as a whole is  mana~eable 
and ·effective  and  allows  uniform  arrangements  across  the  entire  territory  of the 
Union? 
What mechinisms should be established for adapting the rules  in order to  respond 
quickly  to  the  very  marked  changeability  of the  precursors  used  to  manufacture 
NSDs,  in particular in response to information obtained through the cooperation of 
economic operators? 
Would  it  be  wise  to  make  the  list  of precursors  concerned  public,  especially  if, 
through cooperation with operators, the goal is also to pinpoint new developments 
as early as possible and detect suspect orders? 
5.  The Commission's approach 
Commission  departments  are working  with  national  experts  in  an  attempt  to  define  a 
suitable  coherent  system  to  tackle  the  the  problems  of NSDs.  There  are  no  obvious 
answers to the questions listed above and  some technical  w~rk needs to be pursued  in 
greater depth. Contacts with the economic operators concerned also need to be pursued 
in this direction, both at national and Community leve~. 
I 
It  is therefore felt  that the Community reaction on the  issue of the precursors used  for 
making NSDs should focus on the following points: 
(a)  Presentation of  a proposal to amend the Replation on the external aspects (legal 
basis: Article 113 ofthe Treaty). The monitoring mechanisms for the new substances that 
will be defined should not include such measures as the issuing of  licences and should rest 
primarily on  cooperation  with  the  economic  operators  concerned,  bearing  in  mind  the 
positive experience of  some Member States so far and the legitimate concerns of  industry. 
Explicit  provision  could  be  made  for  monitoring  other substances  used  as  precursors, 
provided that the information so gathered is regularly shared· in the Community committee 
on precursors in order to keep pace with developments on the ground. 
(b)  Presentation of a proposal to amend  the Directive on  the  internal  aspects  (legal  · 
basis:  Article  100a  of the  Treaty).  Both  the  mechanism  applied  and  the  substances 
covered would have to be the same as in the proposed amendment to the Regulation.  A 
separate instrument is  needed to  cover the manufacture and  placing on the  Community 
market of  these substances, in addition to their export. 
(c)  Rapid  decision  on  tbe  Community  position  on  the  issue  with  an  eye  to  the 
forthcoming  discussions  in  the  United  Nations.  The  only  way  for  the  Union  and  the 
Member States to exert real influence on the course of  the discussions is to put forward a 
single,  united  position  vis a vis  our  partn~rs. This  is  essential  to  obtain  ·an  effective 
outcome  in  terms  of combating  NSDs  but  also  to  prevent  international  agreement  on 
mechanisms that do not suit our needs and are out of  line with· the approach we want to 
follow.  · (d)  In view of the large volume ofNSDs being made in the countries of Central and 
Eastern Europe (most of  which are seeking membership of  the Union), it is essential, once 
the Community has decided how it wishes to alter its own system, to launch action under 
the  Phare  programme  to  supplement  the  measures  already  taken  in  respect  of these 
countries  in  terms  of preparing  their  legislation  on  precursors.  In  addition,  specific 
agreements should be concluded with them, along ~he lines of  those concluded with other 
non-member countries on precursors, in order to reinforce the overall effectiveness of  our 
respective  arrangements,  since  it  will  be  some  years  before  those  countries  actually 
become members. 
6.  Timetable for action 
To reconcile the need for a swift reaction to the current challenges and the need to finalize 
effective measures,  proposals for measures on points (a) and (b) ought to be ready by 
early autumn. The timing ties in with action on point (c), where the Union will have to be 
ready to put forward the Community position in the appropriate international forums  by 
October. 
As far as action on point (d) is concerned,  this cannot reasonably begin (request to the 
Council for a negotiating brief)  until  the Council  has  adopted the new legislation.  This 
could be early in 1998 if  the Regulation (based on Article 113) is adopted quickly. 
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